Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial.

Mailpoint 813, Level E, South Block, Southampton General Hospital, Southampton SO16 6YD, UK.
Gut (Impact Factor: 13.32). 05/2005; 54(4):540-5. DOI: 10.1136/gut.2004.047563
Source: PubMed

ABSTRACT Proinflammatory cytokines, especially tumour necrosis factor alpha (TNF-alpha), play a prominent role in the pathogenesis of cancer cachexia. Thalidomide, which is an inhibitor of TNF-alpha synthesis, may represent a novel and rational approach to the treatment of cancer cachexia.
To assess the safety and efficacy of thalidomide in attenuating weight loss in patients with cachexia secondary to advanced pancreatic cancer.
Fifty patients with advanced pancreatic cancer who had lost at least 10% of their body weight were randomised to receive thalidomide 200 mg daily or placebo for 24 weeks in a single centre, double blind, randomised controlled trial. The primary outcome was change in weight and nutritional status.
Thirty three patients (16 control, 17 thalidomide) were evaluated at four weeks, and 20 patients (eight control, 12 thalidomide) at eight weeks. At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm(3) in arm muscle mass (AMA) compared with a loss of 2.21 kg (absolute difference -2.59 kg (95% confidence interval (CI) -4.3 to -0.8); p = 0.005) and 4.46 cm(3) (absolute difference -5.6 cm(3) (95% CI -8.9 to -2.2); p = 0.002) in the placebo group. At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm(3) in AMA compared with a loss of 3.62 kg (absolute difference -3.57 kg (95% CI -6.8 to -0.3); p = 0.034) and 8.4 cm(3) (absolute difference -7.9 cm(3) (95% CI -14.0 to -1.8); p = 0.014) in the placebo group. Improvement in physical functioning correlated positively with weight gain (r = 0.56, p = 0.001).
Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Thalidomide removed from market in 1962 because of severe teratogenicity. Recent studies have shown that it has antiangiogenic and immunomodulatory effects. It has now returned to practice as an effective oral agent in the management of various conditions like erythema nodosum leprosum and multiple myeloma. Its use in other tumors is under evaluation, with promise in renal cell carcinoma, ovarian cancer, non small cell lung carcinoma, colorectal carcinoma, prostate cancer, glioma, and Kaposi's sarcoma. It has also shown beneficial activity in cancer related cachexia. The most notorious effect of thalidomide is teratogenicity. Sedation and constipation are known side-effects of thalidomide. Thalidomide also has been associated with neuropathy and deep vein thrombosis. To ensure that fetal exposure to this teratogenic agent does not occur, the manufacturer has instituted a comprehensive program to control prescribing, dispensing, and use of the drug. This program, known as the System for Thalidomide Education and Prescribing Safety (STEPS). The present review examines the background, pharmacokinetics, mechanism of action, adverse effects, and uses of thalidomide in malignancy. Relevant articles were identified through PUBMED searches (1962-2009). Search terms included thalidomide, pharmacokinetics, pharmacology, therapeutic use, and teratogenicity, as well as terms for specific disease states and adverse events. Further publications were identified from the reference lists of the reviewed articles.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Dysfunction and wasting of skeletal muscle as a consequence of illness decreases the length and quality of life. Currently, there are few, if any, effective treatments available to address these conditions. Hence, the existence of this unmet medical need has fuelled large scientific efforts. Fortunately, these efforts have revealed many of the underlying mechanisms adversely affecting skeletal muscle health. With increased understanding have come breakthrough disease-specific and broad spectrum interventions, some progressing through clinical development. This review focuses its attention on the role of antagonistic process regulating skeletal muscle mass before branching into prospective promising therapeutic targets and interventions. Special attentions is given to therapies in development against cancer cachexia and Duchenne Muscular Dystrophy before closing remarks on design and conceptualization of future therapies are presented to the reader.
    Clinical and Experimental Pharmacology and Physiology 10/2014; DOI:10.1111/1440-1681.12320 · 2.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cancer patients experience multiple symptoms throughout their illness trajectory. Symptoms consistently occurring together, known as symptom clusters, share common pathophysiologic mechanisms. Understanding and targeting such symptom clusters may allow for more effective and efficient use of treatments for a variety of symptoms. Fatigue-anorexia-cachexia is one of the most prevalent symptom clusters and significantly impairs quality of life. In this review, we explore the fatigue-anorexia-cachexia symptom cluster and focus on current and emerging therapies with an emphasis on pharmacologic management.
    The Cancer Journal 09/2014; 20(5):325-329. DOI:10.1097/PPO.0000000000000065 · 3.61 Impact Factor


1 Download
Available from